New biologic drug GEN1106 enters first human tests for Hard-to-Treat cancers
NCT ID NCT07416123
First seen Feb 18, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants receive the active drug, and the trial lasts about 17 months per person.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Carolina Urologic Research Center
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
-
Hospital Universitario Quironsalud Madrid
RECRUITINGMadrid, 28223, Spain
-
National Cancer Center Hospital
RECRUITINGChuo Ku, Tokyo, 104-0045, Japan
-
START Madrid - Centro Integral Oncologico Clara Campal
RECRUITINGMadrid, 28050, Spain
-
START Madrid - Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
START New York Long Island LLC
RECRUITINGLake Success, New York, 11042, United States
-
South Texas Accelerated Research Therapeutics
RECRUITINGSan Antonio, Texas, 78229, United States
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06510, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GEN1106 (a biologic drug given by IV infusion)
What this could lead to
If successful, this could point toward a new treatment option for people with certain advanced solid tumors, including bladder cancer.
What could go wrong
This is a very early phase 1 trial with only 103 participants. The main goal is safety, not effectiveness, and many experimental cancer drugs fail in early testing. Side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.